276 related articles for article (PubMed ID: 28489562)
1. Incidence of menopausal symptoms in postmenopausal breast cancer patients treated with aromatase inhibitors.
Hong D; Bi L; Zhou J; Tong Y; Zhao Q; Chen J; Lu X
Oncotarget; 2017 Jun; 8(25):40558-40567. PubMed ID: 28489562
[TBL] [Abstract][Full Text] [Related]
2. Prevalence and risk factors for insomnia among breast cancer patients on aromatase inhibitors.
Desai K; Mao JJ; Su I; Demichele A; Li Q; Xie SX; Gehrman PR
Support Care Cancer; 2013 Jan; 21(1):43-51. PubMed ID: 22584732
[TBL] [Abstract][Full Text] [Related]
3. Arthralgia among women taking aromatase inhibitors: is there a shared inflammatory mechanism with co-morbid fatigue and insomnia?
Bauml J; Chen L; Chen J; Boyer J; Kalos M; Li SQ; DeMichele A; Mao JJ
Breast Cancer Res; 2015 Jun; 17(1):89. PubMed ID: 26126656
[TBL] [Abstract][Full Text] [Related]
4. Aromatase inhibitor therapy: toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancer.
Dent SF; Gaspo R; Kissner M; Pritchard KI
Breast Cancer Res Treat; 2011 Apr; 126(2):295-310. PubMed ID: 21249443
[TBL] [Abstract][Full Text] [Related]
5. Aromatase inhibitor-associated arthralgia syndrome.
Burstein HJ
Breast; 2007 Jun; 16(3):223-34. PubMed ID: 17368903
[TBL] [Abstract][Full Text] [Related]
6. Menopausal-type symptoms among breast cancer patients on aromatase inhibitor therapy.
Gallicchio L; MacDonald R; Wood B; Rushovich E; Helzlsouer KJ
Climacteric; 2012 Aug; 15(4):339-49. PubMed ID: 22191462
[TBL] [Abstract][Full Text] [Related]
7. Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early breast cancer: Putting safety issues into perspective.
Conte P; Frassoldati A
Breast J; 2007; 13(1):28-35. PubMed ID: 17214790
[TBL] [Abstract][Full Text] [Related]
8. Clinical and genetic risk factors for aromatase inhibitor-associated arthralgia in breast cancer survivors.
Romero SAD; Su HI; Satagopan J; Li QS; Seluzicki CM; Dries A; DeMichele AM; Mao JJ
Breast; 2020 Feb; 49():48-54. PubMed ID: 31678641
[TBL] [Abstract][Full Text] [Related]
9. Toxicity of extended adjuvant endocrine with aromatase inhibitors in patients with postmenopausal breast cancer: A Systemtic review and Meta-analysis.
Zhao F; Ren D; Shen G; Ahmad R; Dong L; Du F; Zhao J
Crit Rev Oncol Hematol; 2020 Dec; 156():103114. PubMed ID: 33045493
[TBL] [Abstract][Full Text] [Related]
10. Body mass index and menopausal disorders during menopause affect vasomotor symptoms of postmenopausal Japanese breast cancer patients treated with anastrozole: a prospective multicenter cohort study of patient-reported outcomes.
Tane K; Egawa C; Takao S; Yamagami K; Miyashita M; Baba M; Ichii S; Konishi M; Kikawa Y; Minohata J; Okuno T; Miyauchi K; Wakita K; Suwa H; Hashimoto T; Nishino M; Matsumoto T; Hidaka T; Konishi Y; Sakoda Y; Miya A; Kishimoto M; Nishikawa H; Kono S; Kokufu I; Sakita I; Kitatsuji K; Oh K; Akazawa K; Miyoshi Y
Breast Cancer; 2017 Jul; 24(4):528-534. PubMed ID: 27730528
[TBL] [Abstract][Full Text] [Related]
11. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women.
Mouridsen HT
Curr Med Res Opin; 2006 Aug; 22(8):1609-21. PubMed ID: 16870085
[TBL] [Abstract][Full Text] [Related]
12. Time course of arthralgia among women initiating aromatase inhibitor therapy and a postmenopausal comparison group in a prospective cohort.
Castel LD; Hartmann KE; Mayer IA; Saville BR; Alvarez J; Boomershine CS; Abramson VG; Chakravarthy AB; Friedman DL; Cella DF
Cancer; 2013 Jul; 119(13):2375-82. PubMed ID: 23575918
[TBL] [Abstract][Full Text] [Related]
13. Specific adverse events are associated with response to exemestane therapy in postmenopausal breast cancer patients: Results from the TEAMIIA study (BOOG2006-04).
Fontein DB; Charehbili A; Nortier JW; Putter H; Kranenbarg EM; Kroep JR; Linn SC; van de Velde CJ
Eur J Surg Oncol; 2017 Apr; 43(4):619-624. PubMed ID: 28017458
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant aromatase inhibitor therapy in early breast cancer: what factors lead patients to discontinue treatment?
Moscetti L; Agnese Fabbri M; Sperduti I; Fabrizio N; Frittelli P; Massari A; Pompei L; D'Auria G; Pofi E; Ruggeri EM
Tumori; 2015; 101(5):469-73. PubMed ID: 26108239
[TBL] [Abstract][Full Text] [Related]
15. Sonographic and electrodiagnostic evaluations in patients with aromatase inhibitor-related arthralgia.
Dizdar O; Ozçakar L; Malas FU; Harputluoglu H; Bulut N; Aksoy S; Ozisik Y; Altundag K
J Clin Oncol; 2009 Oct; 27(30):4955-60. PubMed ID: 19752344
[TBL] [Abstract][Full Text] [Related]
16. Weight gain is associated with increased risk of hot flashes in breast cancer survivors on aromatase inhibitors.
Su HI; Sammel MD; Springer E; Freeman EW; DeMichele A; Mao JJ
Breast Cancer Res Treat; 2010 Nov; 124(1):205-11. PubMed ID: 20182796
[TBL] [Abstract][Full Text] [Related]
17. The CIRAS study: a case control study to define the clinical, immunologic, and radiographic features of aromatase inhibitor-induced musculoskeletal symptoms.
Shanmugam VK; McCloskey J; Elston B; Allison SJ; Eng-Wong J
Breast Cancer Res Treat; 2012 Jan; 131(2):699-708. PubMed ID: 22076476
[TBL] [Abstract][Full Text] [Related]
18. Effectively nursing patients receiving aromatase inhibitor therapy.
Wengström Y
Breast; 2008 Jun; 17(3):227-38. PubMed ID: 18077168
[TBL] [Abstract][Full Text] [Related]
19. Ageing perceptions and non-adherence to aromatase inhibitors among breast cancer survivors.
Brier MJ; Chambless DL; Chen J; Mao JJ
Eur J Cancer; 2018 Mar; 91():145-152. PubMed ID: 29329697
[TBL] [Abstract][Full Text] [Related]
20. Feasibility and promise of a 6-week program to encourage physical activity and reduce joint symptoms among elderly breast cancer survivors on aromatase inhibitor therapy.
Nyrop KA; Muss HB; Hackney B; Cleveland R; Altpeter M; Callahan LF
J Geriatr Oncol; 2014 Apr; 5(2):148-55. PubMed ID: 24495696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
